专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09068020B2 CD133 epitopes 有权
标题翻译： CD133表位
公开(公告)号：US09068020B2
公开(公告)日：2015-06-30
申请号：US12552945
申请日：2009-09-02
申请人： John S. Yu , Keith L. Black , Gentao Liu
发明人： John S. Yu , Keith L. Black , Gentao Liu
IPC分类号： A61K39/00 , C07K14/705 , C07K7/06 , A61K45/06
CPC分类号： C07K14/70596 , A61K39/0011 , A61K45/06 , C07K7/06
摘要： An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.
摘要翻译：免疫原包括具有氨基酸序列ILSAFSVYV（SEQ ID NO：1）为4个或更少的氨基酸取代的800个氨基酸残基的分离的肽，SEQ ID NO：1的超调变体，或具有SEQ ID NO：1的氨基酸序列式（I / K / T / V / M）-L-（S / L） - （A / E / N / D / Q） - （F / V） - （S / M / V / （V / D / R / G / H）-Y-（V / I / L）（SEQ ID NO：13）。免疫原可用于组合物和治疗疾病。

2. 发明授权

US08871211B2 Cancer vaccines and vaccination methods 有权
标题翻译：癌症疫苗和疫苗接种方法
公开(公告)号：US08871211B2
公开(公告)日：2014-10-28
申请号：US11863990
申请日：2007-09-28
申请人： John S. Yu , Gentao Liu , Keith L. Black
发明人： John S. Yu , Gentao Liu , Keith L. Black
IPC分类号： A61K39/00 , C12N5/0784 , A61K35/12
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/545 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/2304 , C12N2501/25 , C12N2501/998 , C12N2506/11
摘要： Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
摘要翻译：本文提供了通过树突状细胞疫苗接种治疗癌症（如神经癌）的方法和组合物。

3. 发明授权

US08097256B2 Cancer vaccines and vaccination methods 有权
标题翻译：癌症疫苗和疫苗接种方法
公开(公告)号：US08097256B2
公开(公告)日：2012-01-17
申请号：US11864177
申请日：2007-09-28
申请人： John S. Yu , Gentao Liu , Keith L. Black
发明人： John S. Yu , Gentao Liu , Keith L. Black
IPC分类号： A61K39/00 , C12P21/00
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/545 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/2304 , C12N2501/25 , C12N2501/998 , C12N2506/11
摘要： Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
摘要翻译：本文提供了通过树突状细胞疫苗接种治疗癌症（如神经癌）的方法和组合物。

4. 发明授权

US09433667B2 Cancer vaccines and vaccination methods 有权
公开(公告)号：US09433667B2
公开(公告)日：2016-09-06
申请号：US13327125
申请日：2011-12-15
申请人： John S. Yu , Gentao Liu , Keith L. Black
发明人： John S. Yu , Gentao Liu , Keith L. Black
IPC分类号： A61K39/00 , C12N5/0784 , A61K35/12
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/545 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/2304 , C12N2501/25 , C12N2501/998 , C12N2506/11
摘要： Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.

5. 发明申请

US20120156232A1 CANCER VACCINES AND VACCINATION METHODS 有权
标题翻译：癌症疫苗和疫苗接种方法
公开(公告)号：US20120156232A1
公开(公告)日：2012-06-21
申请号：US13327125
申请日：2011-12-15
申请人： John S. Yu , Gentao Liu , Keith L. Black , Clemencia Pinilla
发明人： John S. Yu , Gentao Liu , Keith L. Black , Clemencia Pinilla
IPC分类号： A61K39/00 , C12N5/02
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/545 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/2304 , C12N2501/25 , C12N2501/998 , C12N2506/11
摘要： Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
摘要翻译：本文提供了通过树突状细胞疫苗接种治疗癌症（如神经癌）的方法和组合物。

6. 发明申请

US20100135975A1 CD133 Epitopes 有权
标题翻译： CD133表位
公开(公告)号：US20100135975A1
公开(公告)日：2010-06-03
申请号：US12552945
申请日：2009-09-02
申请人： John S. Yu , Keith L. Black , Gentao Liu
发明人： John S. Yu , Keith L. Black , Gentao Liu
IPC分类号： A61K45/00 , C07K7/06 , A61K39/00 , C07H21/00 , C12N15/74 , A61K31/7088 , C12N5/0783 , A61P35/00 , A61P37/04
CPC分类号： C07K14/70596 , A61K39/0011 , A61K45/06 , C07K7/06
摘要： An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.
摘要翻译：免疫原包括具有氨基酸序列ILSAFSVYV（SEQ ID NO：1）为4个或更少的氨基酸取代的800个氨基酸残基的分离的肽，SEQ ID NO：1的超调变体，或具有SEQ ID NO：1的氨基酸序列式（I / K / T / V / M）-L-（S / L） - （A / E / N / D / Q） - （F / V） - （S / M / V / （V / D / R / G / H）-Y-（V / I / L）（SEQ ID NO：13）。免疫原可用于组合物和治疗疾病。

7. 发明申请

US20080311142A1 CANCER VACCINES AND VACCINATION METHODS 有权
标题翻译：癌症疫苗和疫苗接种方法
公开(公告)号：US20080311142A1
公开(公告)日：2008-12-18
申请号：US11864177
申请日：2007-09-28
申请人： John S. Yu , Gentao Liu , Keith L. Black , Clemencia Pinilla
发明人： John S. Yu , Gentao Liu , Keith L. Black , Clemencia Pinilla
IPC分类号： A61K39/00 , A61K35/12 , A61P31/00
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/545 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/2304 , C12N2501/25 , C12N2501/998 , C12N2506/11
摘要： Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
摘要翻译：本文提供了通过树突状细胞疫苗接种治疗癌症（如神经癌）的方法和组合物。

8. 发明授权

US06774119B1 HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)-DERIVED VECTOR FOR SELECTIVELY INHIBITING MALIGNANT CELLS AND METHODS FOR ITS USE TO TREAT CANCERS AND TO EXPRESS DESIRED TRAITS IN MALIGNANT AND NON-MALIGNANT MAMMALIAN CELLS 有权
标题翻译：用于选择性抑制恶性细胞的HERPES SIMPLEX病毒1型（HSV-1）载体及其用于治疗癌症并在恶性和非恶性肿瘤细胞中表达所需的病原体的方法
公开(公告)号：US06774119B1
公开(公告)日：2004-08-10
申请号：US09299817
申请日：1999-04-26
申请人： Steven L. Wechsler , Anthony B. Nesburn , Guey-Chuen Perng , John S. Yu , Keith L. Black
发明人： Steven L. Wechsler , Anthony B. Nesburn , Guey-Chuen Perng , John S. Yu , Keith L. Black
IPC分类号： A61K4800
CPC分类号： C12N7/00 , A61K39/00 , A61K48/00 , C07K14/005 , C12N15/86 , C12N2710/16622 , C12N2710/16643 , C12N2710/16661
摘要： Disclosed is a method of selectively inhibiting the growth of malignant cells in mammals, including humans. The method selectively inhibits the growth of malignant cells of all varieties, and is particularly useful in treating brain tumors and other malignancies of the central nervous system. The method employs HSV-1-derived vectors containing a DNA having a deletion in both copies of the LAT gene and both copies of the ICP34.5 gene of HSV-1. The vectors are delivered to malignant cells either in vivo or in vitro, in accordance with the method. The HSV-1-derived expression vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid having a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-&ggr;. A method of expressing in a mammalian cell a gene encoding a preselected protein, a method of treating a genetic defect, and a method of detecting an HSV-1 expressing cell also employ vectors of the present invention that contain at least one transcriptional unit of a constitutive LAT promoter operatively linked to and controlling the transcription of a gene encoding a preselected protein. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, useful for practicing the methods, and mammalian cells containing the HSV-derived vectors.
摘要翻译：公开了一种选择性抑制包括人在内的哺乳动物中恶性细胞生长的方法。该方法选择性地抑制所有品种的恶性细胞的生长，并且特别可用于治疗中枢神经系统的脑肿瘤和其他恶性肿瘤。该方法使用含有两个拷贝的LAT基因和HSV-1的ICP34.5基因的两个拷贝的具有缺失的DNA的HSV-1衍生载体。根据该方法，在体内或体外将载体递送至恶性细胞。 HSV-1衍生的表达载体是非神经毒性的，并且不会从潜伏期自发地再激活，并且它们任选地含有功能性HSV胸苷激酶基因，其可以增强用喷昔洛维或阿昔洛韦进行药物治疗的癌症的有效性。或者，HSV-1衍生的载体含有至少一个LAT启动子序列的转录单位，该转录单位可操作地连接到具有编码对表达载体的细胞有毒的多肽的核苷酸序列的核酸，例如人类干扰素-γ。在哺乳动物细胞中表达编码预选蛋白质的基因，治疗遗传缺陷的方法和检测表达HSV-1的细胞的方法的方法也采用本发明的载体，其含有至少一个转录单位组成型LAT启动子与编码预选蛋白质的基因的转录有效连接并控制其转录。此外，公开了用于在哺乳动物细胞中表达编码用于实施该方法的预选蛋白质的基因和含有HSV衍生载体的哺乳动物细胞的试剂盒。

9. 发明授权

US06838279B2 Herpes simplex virus type 1 (HSV-1)-derived vector for selectively inhibiting malignant cells and for expressing desired traits in malignant and non-malignant mammalian cells 失效
标题翻译：用于选择性抑制恶性细胞并在恶性和非恶性哺乳动物细胞中表达所需性状的单纯疱疹病毒1型（HSV-1）衍生载体
公开(公告)号：US06838279B2
公开(公告)日：2005-01-04
申请号：US10046491
申请日：2001-10-29
申请人： Steven L. Wechsler , Anthony B. Nesburn , Guey-Chuen Perng , John S. Yu , Keith L. Black
发明人： Steven L. Wechsler , Anthony B. Nesburn , Guey-Chuen Perng , John S. Yu , Keith L. Black
IPC分类号： A61K39/00 , A61K48/00 , A61P35/00 , C07K14/035 , C12N7/04 , C12N15/38 , C12N15/869 , C12N5/00 , C12N15/63 , C12N15/87
CPC分类号： C12N7/00 , A61K39/00 , A61K48/00 , C07K14/005 , C12N15/86 , C12N2710/16622 , C12N2710/16643 , C12N2710/16661
摘要： Disclosed is an HSV-1-derived vector containing a DNA having a functional LAT promoter, or operative fragment thereof, a deletion in both copies of the HSV-1 LAT gene, and a deletion in both copies of the HSV-1 ICP34.5 gene. The HSV-1-derived vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid encoding a preselected protein. In some embodiments, the preselected protein is a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-γ. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, and mammalian cells containing the HSV-derived vectors.
摘要翻译：公开了含有具有功能性LAT启动子的DNA或其手术片段的HSV-1衍生载体，HSV-1 LAT基因的两个拷贝中的缺失和HSV-1 ICP34.5的两个拷贝中的缺失基因。 HSV-1衍生的载体是非神经毒性的，并且不会从潜伏期自发地再激活，并且它们任选地含有功能性HSV胸苷激酶基因，其可以增强用胍基洛尔或阿昔洛韦进行药物治疗的癌症的有效性。或者，来自HSV-1的载体含有与编码预选蛋白质的核酸可操作地连接的LAT启动子序列的至少一个转录单位。在一些实施方案中，预选蛋白质是编码对表达载体例如人干扰素-γ的细胞有毒的多肽的核苷酸序列。此外，公开了用于在哺乳动物细胞中表达编码预选蛋白质的基因的试剂盒和含有HSV衍生载体的哺乳动物细胞。

10. 发明授权

US07129034B2 Differentiation of whole bone marrow 有权
公开(公告)号：US07129034B2
公开(公告)日：2006-10-31
申请号：US10253759
申请日：2002-09-24
申请人： John S. Yu , Peter Kabos , Moneeb Ehtesham
发明人： John S. Yu , Peter Kabos , Moneeb Ehtesham
IPC分类号： C12N5/00 , C12N5/06 , C12N5/08 , C12N5/10
CPC分类号： C12N5/0623 , A61K35/12 , A61K38/00 , A61K48/00 , C12N2501/11 , C12N2501/115 , C12N2506/11 , C12N2506/1353 , C12N2510/00
摘要： A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式